Resistance to targeted drugs does not necessarily mean that there is no way out, because tumors are constantly evolving and changing, and resistance may be due to new genetic mutations. For example, in non-small cell lung cancer, like lung adenocarcinoma with EGFR mutation, the first-line targeted drugs are Erysal and Troche, etc. If resistance occurs, genetic testing should be continued, and if there is ALK mutation, crizotinib can be applied. In addition, other second- and third-line drugs targeting EGFR mutations, Tereza can be considered for use. In addition to these, there is the newly released Anrotinib, which can be used for second and third line targeted therapy for non-small cell lung cancer, and does not require genetic testing.